<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530582</url>
  </required_header>
  <id_info>
    <org_study_id>KAD 108 ex</org_study_id>
    <nct_id>NCT00530582</nct_id>
  </id_info>
  <brief_title>Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women</brief_title>
  <official_title>Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max-Planck-Institute of Psychiatry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Kade/Besins Pharma GmbH, Rigistr. 2, 12277 Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Max-Planck-Institute of Psychiatry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep is impaired in postmenopausal women (difficulty falling asleep, frequent awakenings).&#xD;
      Progesterone prompted benzodiazepine-like effects on sleep EEG in young normal male subjects.&#xD;
&#xD;
      Aim of this study was to test if replacement therapy with progesterone improves sleep after&#xD;
      menopause.&#xD;
&#xD;
      Design, Setting, and Participants: A double blind cross-over design study with 2 treatment&#xD;
      intervals of 21 days duration separated by a 2 weeks washout was performed. A oral dose of&#xD;
      300mg micronized progesterone was given each for 21 days. At the beginning and the end of the&#xD;
      two intervals a sleep EEG was recorded and cognitive performance was assessed in 10 healthy&#xD;
      postmenopausal women (age: 54-70 yrs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives/ Mode of administration: To characterise the effects of progesterone in a dose of&#xD;
      300mg each for 21 days on changes of sleep EEG and cognition in postmenopausal healthy women,&#xD;
      in comparison with placebo.&#xD;
&#xD;
      Methodology:The study was performed as double blind randomized placebo controlled crossover&#xD;
      design with two treatment intervals of 21 days duration separated by 2 weeks washout.&#xD;
      Progesterone was administered as tablets in a dose of 300mg each for 21 days. At the&#xD;
      beginning and the end of the two intervals a sleep EEG was recorded after one night of&#xD;
      adaptation to laboratory conditions, during which EEG electrodes were attached without&#xD;
      recording an EEG.For the registration nights the subjects arrived at the sleep laboratory at&#xD;
      21.00 h. Sleep EEG was recorded from 23.00 h until 07.00 h hours next morning.Cognitive&#xD;
      performance was tested after the registration nights at 09.00h.All pharmacodynamic&#xD;
      investigations were carried out in the sleep laboratory of the Max Planck Institute of&#xD;
      Psychiatry in Munich.&#xD;
&#xD;
      Main criteria for inclusion: Subjects consisted of 10 healthy women (age: range 54-70 years)&#xD;
      who entered the study after passing rigid psychiatric, physical and laboratory examinations.&#xD;
      They had been drug free at least 4 weeks. Reasons for exclusion from the study were:&#xD;
      psychiatric disorder in the subjects own or family history, including dementia or other&#xD;
      cognitive impairment; recent stressful life events; substance abuse; a transmeridian flight&#xD;
      during the last three months; shift work; medical illness; and aberrations in blood chemistry&#xD;
      or in the waking EEG or electrocardiogram.All subjects underwent a polysomnographic&#xD;
      examination in the sleep laboratory before entering the study to exclude sleep disorder&#xD;
      including sleep related respiratory disorders and sleep related movement disorders.&#xD;
&#xD;
      Statistical methode: Expolatory and inferential statistical analysis of certain aggregated&#xD;
      sleep variables after classifying the sleep EEG in dinstinct stages according to&#xD;
      Rechtschafen/Kales and of the results of EEG spectral analysis. Inferential statistics were&#xD;
      based on multivariate analyses of variance (MANOVAs) with treatment as influential factor and&#xD;
      on one sample t-tests for placebo related power changes of progesterone in non-REM sleep as&#xD;
      well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep-EEG parameters</measure>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <condition>Postmenopausal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>progesterone</intervention_name>
    <description>300mg progesterone /placebo each for 21 days</description>
    <other_name>Utrogest/ Utrogest Placebo Ch.-B.: 0503</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy female elderly subjects&#xD;
&#xD;
          -  Age between 55-70 years&#xD;
&#xD;
          -  Normal physical examination including a neurological and gynecological examination&#xD;
&#xD;
          -  Medical history without major or chronic diseases (e.g. diabetes, heart failure,&#xD;
             hepatitis)&#xD;
&#xD;
          -  No previous psychiatric or chronic neurological disorder (e.g. schizophrenia,&#xD;
             epilepsy)&#xD;
&#xD;
          -  Normal standard electrocardiograpy (ECG)&#xD;
&#xD;
          -  Normal laboratory results&#xD;
&#xD;
          -  Body Mass Index &lt;30&#xD;
&#xD;
          -  Normal sleep EEG concerning restless leg and sleep apnoe syndrom&#xD;
&#xD;
          -  Normal EEG, according to the guidelines of the Deutsche EEG Gesellschaft (German EEG&#xD;
             Society)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Written consent from the gynecologist, who examined the subjects, that there is no&#xD;
             contradiction for the oral application of Utrogest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal disorder&#xD;
&#xD;
          -  Gynecological disorder&#xD;
&#xD;
          -  Heart and lung disorder&#xD;
&#xD;
          -  Liver and kidney disorders&#xD;
&#xD;
          -  Creatinin serum &gt;2,5 mg%&#xD;
&#xD;
          -  Thyroid diseases&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  Psychiatric disorder in the family history&#xD;
&#xD;
          -  Peripheral and central nervous system disorder&#xD;
&#xD;
          -  Metabolic diseases&#xD;
&#xD;
          -  Endocrine diseases&#xD;
&#xD;
          -  Muscular or dermatological diseases&#xD;
&#xD;
          -  Haematological diseases&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
        Further exclusion criteria were:&#xD;
&#xD;
          -  Sleeping disorder&#xD;
&#xD;
          -  Shift work&#xD;
&#xD;
          -  Transmerdian flight in the last three months&#xD;
&#xD;
          -  Malignant diseases&#xD;
&#xD;
          -  Acute infective diseases&#xD;
&#xD;
          -  Clinically relevant allergies&#xD;
&#xD;
          -  Lack of compliance to study procedures&#xD;
&#xD;
          -  Participation in another clinical study within the last 4 month&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>54 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Steiger, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Max-Planck-Institute of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Max Planck Institute of Psychiatry</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Dzaja A, Arber S, Hislop J, Kerkhofs M, Kopp C, Pollmacher T, Polo-Kantola P, Skene DJ, Stenuit P, Tobler I, Porkka-Heiskanen T. Women's sleep in health and disease. J Psychiatr Res. 2005 Jan;39(1):55-76. Ehlers CL, Kupfer DJ. Slow-wave sleep: do young adult men and women age differently? J Sleep Res. 1997 Sep;6(3):211-5. Friess E, Tagaya H, Trachsel L, Holsboer F, Rupprecht R. Progesterone-induced changes in sleep in male subjects. American Journal of Physiology: Endocrinology &amp; Metabolism 1997; 272:E885-E891. Gr√∂n G, Friess E, Herpers M, Rupprecht R. Assessment of cognitive performance after progesterone administration in healthy male volunteers. Biol Psychiatry 1997; 35:147-151. Heuser G, Ling GM, Kluver M. Sleep induction by progesterone in the pre-optic area in cats. Electroencephalography &amp; Clinical Neurophysiology 1966; 22:122-127. Lancel M, Faulhaber J, Schiffelholz T, Romeo E, Di Michele F, Holsboer F, Rupprecht R. Allopregnanolone affects sleep in a benzodiazepine-like fashion. Journal of Pharmacology &amp; Experimental Therapeutics 1997; 282(3):1213-1218. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001;10-16. Steiger A, Trachsel L, Guldner J, Hemmeter U, Rothe B, Rupprecht R, Vedder H, Holsboer F. Neurosteroid pregnenolone induces sleep-EEG changes in man compatible with inverse agonistic GABAA-receptor modulation. Brain Research 1993; 615:267-274.</citation>
  </reference>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 14, 2007</study_first_submitted>
  <study_first_submitted_qc>September 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <last_update_submitted>September 14, 2007</last_update_submitted>
  <last_update_submitted_qc>September 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2007</last_update_posted>
  <keyword>progesterone, postmenopause, sleep-EEG</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

